Literature DB >> 26818619

Global patterns and trends in colorectal cancer incidence and mortality.

Melina Arnold1, Mónica S Sierra1, Mathieu Laversanne1, Isabelle Soerjomataram1, Ahmedin Jemal2, Freddie Bray1.   

Abstract

OBJECTIVE: The global burden of colorectal cancer (CRC) is expected to increase by 60% to more than 2.2 million new cases and 1.1 million deaths by 2030. In this study, we aim to describe the recent CRC incidence and mortality patterns and trends linking the findings to the prospects of reducing the burden through cancer prevention and care.
DESIGN: Estimates of sex-specific CRC incidence and mortality rates in 2012 were extracted from the GLOBOCAN database. Temporal patterns were assessed for 37 countries using data from Cancer Incidence in Five Continents (CI5) volumes I-X and the WHO mortality database. Trends were assessed via the annual percentage change using joinpoint regression and discussed in relation to human development levels.
RESULTS: CRC incidence and mortality rates vary up to 10-fold worldwide, with distinct gradients across human development levels, pointing towards widening disparities and an increasing burden in countries in transition. Generally, CRC incidence and mortality rates are still rising rapidly in many low-income and middle-income countries; stabilising or decreasing trends tend to be seen in highly developed countries where rates remain among the highest in the world.
CONCLUSIONS: Patterns and trends in CRC incidence and mortality correlate with present human development levels and their incremental changes might reflect the adoption of more western lifestyles. Targeted resource-dependent interventions, including primary prevention in low-income, supplemented with early detection in high-income settings, are needed to reduce the number of patients with CRC in future decades. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  COLORECTAL CANCER; EPIDEMIOLOGY

Mesh:

Year:  2016        PMID: 26818619     DOI: 10.1136/gutjnl-2015-310912

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  1248 in total

1.  Invitation to Screening Colonoscopy in the Population at Familial Risk for Colorectal Cancer.

Authors:  Alexander Bauer; Jürgen F Riemann; Thomas Seufferlein; Max Reinshagen; Stephan Hollerbach; Ulrike Haug; Susanne Unverzagt; Stephanie Boese; Madeleine Ritter-Herschbach; Patrick Jahn; Thomas Frese; Michael Harris; Margarete Landenberger
Journal:  Dtsch Arztebl Int       Date:  2018-10-26       Impact factor: 5.594

2.  Improved Antitumor Activity of the Fluoropyrimidine Polymer CF10 in Preclinical Colorectal Cancer Models through Distinct Mechanistic and Pharmacologic Properties.

Authors:  William H Gmeiner; Anthony Dominijanni; Alex O Haber; Lais P Ghiraldeli; David L Caudell; Ralph D'Agostino; Boris C Pasche; Thomas L Smith; Zhiyong Deng; Sezgin Kiren; Chinnadurai Mani; Komaraiah Palle; Jonathan R Brody
Journal:  Mol Cancer Ther       Date:  2020-12-23       Impact factor: 6.261

3.  Colon cancer stem cells: Potential target for the treatment of colorectal cancer.

Authors:  Riya Gupta; Lokesh Kumar Bhatt; Thomas P Johnston; Kedar S Prabhavalkar
Journal:  Cancer Biol Ther       Date:  2019-05-03       Impact factor: 4.742

4.  Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis.

Authors:  Diana Groza; Sebastian Gehrig; Pavol Kudela; Martin Holcmann; Christine Pirker; Carina Dinhof; Hemma H Schueffl; Marek Sramko; Julia Hoebart; Fatih Alioglu; Michael Grusch; Manfred Ogris; Werner Lubitz; Bernhard K Keppler; Irena Pashkunova-Martic; Christian R Kowol; Maria Sibilia; Walter Berger; Petra Heffeter
Journal:  Oncoimmunology       Date:  2018-02-16       Impact factor: 8.110

5.  Aquaporin 1 expression is associated with response to adjuvant chemotherapy in stage II and III colorectal cancer.

Authors:  Hideko Imaizumi; Keiichiro Ishibashi; Seiichi Takenoshita; Hideyuki Ishida
Journal:  Oncol Lett       Date:  2018-03-05       Impact factor: 2.967

6.  Improving anticancer activity towards colon cancer cells with a new p53-activating agent.

Authors:  Liliana Raimundo; Margarida Espadinha; Joana Soares; Joana B Loureiro; Marco G Alves; Maria M M Santos; Lucília Saraiva
Journal:  Br J Pharmacol       Date:  2018-09-06       Impact factor: 8.739

Review 7.  Capecitabine Versus Continuous Infusion Fluorouracil for the Treatment of Advanced or Metastatic Colorectal Cancer: a Meta-analysis.

Authors:  Zehua Wu; Yanhong Deng
Journal:  Curr Treat Options Oncol       Date:  2018-11-27

8.  Recent Advances in Design of Fluorescence-Based Assays for High-Throughput Screening.

Authors:  Xiaoni Fang; Yongzan Zheng; Yaokai Duan; Yang Liu; Wenwan Zhong
Journal:  Anal Chem       Date:  2018-12-10       Impact factor: 6.986

9.  Platelet and Neutrophil Counts as Predictive Markers of Neoadjuvant Therapy Efficacy in Rectal Cancer.

Authors:  AnnaLee Policicchio; Joey Mercier; Antonia Digklia; Ioannis A Voutsadakis
Journal:  J Gastrointest Cancer       Date:  2019-12

10.  How does inflammation drive mutagenesis in colorectal cancer?

Authors:  Chia Wei Hsu; Mark L Sowers; Willie Hsu; Eduardo Eyzaguirre; Suimin Qiu; Celia Chao; Charles P Mouton; Yuri Fofanov; Pomila Singh; Lawrence C Sowers
Journal:  Trends Cancer Res       Date:  2017
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.